It is important to note that bumetanide, an NKCC1 inhibitor, has shown positive therapeutic effects in alleviating symptoms in ASD, Alzheimer’s disease, and stress-related disorders (49, 84, 93, 120–122). Here, SLC12A2 is linked to early-onset autosomal dominant Alzheimer disease.